Remternetug vs SHR-1707
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
Remternetug
Developed by Eli Lilly
NCT05463731 · Phase 3 · completed
The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.
Next expected readout: April 2029 · NCT06653153 (registry estimate)
No aligned efficacy figure on record for this race.
SHR-1707
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05681819 · Phase 1 · completed
The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Remternetug | SHR-1707 |
|---|---|---|
| CDR-SB, change | —Not posted · NCT05463731 | —Not reported |
| ADAS-Cog11, change | —Not posted · NCT05463731 | —Not reported |
| ADCS-ADL, change | —Not posted · NCT05463731 | —Not reported |
| MMSE, change | —Not posted · NCT05463731 | —Not reported |
| Amyloid PET, change (centiloids) | —Not posted · NCT05463731 | —Not reported |
CDR-SB, change
- Remternetug
- —Not posted · NCT05463731
- SHR-1707
- —Not reported
ADAS-Cog11, change
- Remternetug
- —Not posted · NCT05463731
- SHR-1707
- —Not reported
ADCS-ADL, change
- Remternetug
- —Not posted · NCT05463731
- SHR-1707
- —Not reported
MMSE, change
- Remternetug
- —Not posted · NCT05463731
- SHR-1707
- —Not reported
Amyloid PET, change (centiloids)
- Remternetug
- —Not posted · NCT05463731
- SHR-1707
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Remternetug: no structured comparison results are available for Alzheimer's Disease.
SHR-1707: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Remternetug's landscape · SHR-1707's landscape